MOTS-c vs SS-31: How These Two Mitochondrial Peptides Differ

MOTS-c and SS-31 are both mitochondria-focused research peptides, but they are different molecules with different origins and different mechanisms. MOTS-c is a naturally occurring 16-amino-acid peptide encoded in mitochondrial DNA that influences metabolism through AMPK signaling, while SS-31 (elamipretide) is a synthetic four-amino-acid peptide that binds cardiolipin on the inner mitochondrial membrane to protect energy production. Neither peptide is FDA-approved for human use in the United States.

What Are MOTS-c and SS-31?

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. Researchers first described it in 2015 as a mitochondrial-derived peptide that can travel from the mitochondria to the nucleus when a cell is under metabolic stress. The body produces MOTS-c on its own, and circulating levels appear to fall with age and rise with exercise.

SS-31 is entirely synthetic. It belongs to the Szeto-Schiller family of cell-penetrating peptides, which were designed to concentrate in the inner mitochondrial membrane rather than the cytoplasm.

MOTS-c: quick profile

• 16 amino acids, encoded in mitochondrial DNA
• Acts as a metabolic signal and activates AMPK
• Studied mainly for insulin sensitivity, glucose handling, obesity, and exercise capacity
• Human safety and dosing data are extremely limited

SS-31: quick profile

• Four amino acids (D-Arg-Dmt-Lys-Phe-NH2), made in a laboratory
• Binds cardiolipin and reduces oxidative damage to the inner mitochondrial membrane
• Studied in Barth syndrome, primary mitochondrial myopathy, heart failure, kidney injury, and age-related macular degeneration
• Has been tested in multiple human clinical trials

MOTS-c vs SS-31: Side-by-Side Comparison

Feature	MOTS-c	SS-31 (elamipretide)
Origin	Naturally occurring, encoded in mitochondrial DNA	Synthetic, designed in a lab
Size	16 amino acids	4 amino acids
Primary target	AMPK pathway and nuclear gene regulation	Cardiolipin on the inner mitochondrial membrane
Main effect studied	Metabolic regulation, insulin sensitivity, glucose handling	Membrane stability, reduced reactive oxygen species, ATP efficiency
Route in research	Subcutaneous injection in animal work	Subcutaneous injection or intravenous infusion
Human trial data	Very limited	Multiple completed and ongoing trials
FDA status	Not approved for human use	Not approved for human use

How Their Mechanisms Differ

MOTS-c behaves like a metabolic messenger. Under stress, it moves into the nucleus and influences which genes get expressed, which is how it activates AMPK and shifts cells toward greater glucose uptake and fat oxidation. Anyone comparing mots-c vs semaglutide is really comparing a mitochondrial signaling peptide with a GLP-1 receptor agonist, and those two work through entirely separate biology.

SS-31 works locally instead of systemically. It docks onto cardiolipin, protects that lipid from oxidation, and helps the electron transport chain run more efficiently. The difference matters for how studies are designed: MOTS-c research tends to measure whole-body metabolism, while SS-31 research tends to measure tissue-level energy failure.

Where the Human Research Stands

SS-31 has the deeper clinical record. Elamipretide has been studied in trials for Barth syndrome, primary mitochondrial myopathy, heart failure after a heart attack, and age-related macular degeneration. Results across those programs have been mixed, and regulators have not approved elamipretide for any indication.

MOTS-c research is still mostly preclinical. Mouse and cell studies show effects on insulin sensitivity, diet-induced obesity, and exercise capacity, but there is no established human dosing and no large human safety dataset.

These peptides often come up in the same conversations as other metabolic compounds. Investigators who focus on body composition sometimes weigh tesamorelin vs mots-c to compare a growth-hormone-releasing pathway with a mitochondrial one. Others look at nad plus vs mots c when they want to understand how NAD+ availability and mitochondrial signaling interact. Similar questions appear in aod 9604 vs mots-c and lipo c vs mots c discussions, where fat-metabolism research is compared with mitochondrial research.

Dosing and Administration in Research Settings

No standardized human dose exists for MOTS-c outside of research settings, and published animal work has used injected routes with a variety of protocols. SS-31 has defined doses only inside clinical trials, and those doses were chosen for specific diseases rather than general use.

Parameter	MOTS-c	SS-31 (elamipretide)
Established human dose	None	None outside trials
Dosing seen in trials	Not applicable	Roughly 40 mg subcutaneous daily in Barth syndrome studies; intravenous infusions in heart failure studies
Common research route	Subcutaneous injection (animal studies)	Subcutaneous injection or intravenous infusion
Frequency	Not standardized	Once daily or continuous infusion, depending on the trial

Any dose copied from a clinical trial or an animal study is not a recommendation for human use. Trial doses are matched to a specific disease, a specific population, and close medical supervision.

Safety, Sourcing, and Legal Status

Neither MOTS-c nor SS-31 is FDA-approved for human use in the United States. Products sold online are typically labeled as research chemicals and are not for human consumption, which means purity, sterility, and actual peptide content are not guaranteed.

• Reported side effects in elamipretide trials have mostly been mild injection-site reactions, but long-term effects are unknown.
• MOTS-c has almost no human safety data, so its risk profile in people is essentially uncharacterized.
• Unregulated peptides carry added risks, including contamination, incorrect dosing, and immune reactions.
• Anyone considering either peptide for a health condition should talk with a licensed healthcare professional first.

Key Takeaways

• MOTS-c is a naturally occurring 16-amino-acid peptide encoded in mitochondrial DNA, while SS-31 is a synthetic four-amino-acid peptide designed in a lab.
• MOTS-c works mainly through AMPK signaling and metabolic regulation, while SS-31 works mainly by binding cardiolipin on the inner mitochondrial membrane.
• SS-31 has substantially more human clinical trial data than MOTS-c, but it still has not been approved by the FDA for any indication.
• Neither peptide is a proven treatment, and neither has an established human dose for general use.

COMMON QUESTIONS

Frequently Asked Questions

Is MOTS-c the same as SS-31?

No. MOTS-c is a naturally occurring 16-amino-acid peptide encoded in mitochondrial DNA that regulates metabolism through AMPK signaling. SS-31, also called elamipretide, is a synthetic four-amino-acid peptide that binds cardiolipin on the inner mitochondrial membrane to reduce oxidative stress.

Is either MOTS-c or SS-31 FDA approved?

Neither MOTS-c nor SS-31 is FDA-approved for human use in the United States. SS-31 has been tested in human clinical trials for conditions such as Barth syndrome and heart failure, but it has not received approval for any indication.

Which has more human research, MOTS-c or SS-31?

SS-31 has far more human data. Elamipretide has been evaluated in multiple clinical trials, while MOTS-c research remains mostly preclinical, with findings coming from cell and animal studies rather than large human trials.